Eli Lilly to Buy Merida Biosciences in Deal Worth up to $2.88 Billion
8 Articles
8 Articles
Lilly to Buy Merida for $2.88 Billion for Autoimmune Expansion
Eli Lilly & Co. plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world.
Eli Lilly continues its rapid pace of acquisitions and has announced an agreement to buy the biotechnology company Merida Biosciences for up to US$2.87 billion, strengthening the pharmaceutical company's immunology portfolio. Exclusive content for subscribers. For full access, follow the link to the article and register.
Pharmaceutical company and Novo Nordisk competitor Eli Lilly intends to buy biotechnology company Merida for up to $2.88 billion, equivalent to SEK 27.6 billion, in cash.
Eli Lilly has agreed to pay up to $2.875 billion in cash to acquire biotech company Merida Biosciences.
U.S. pharmaceutical company Eli Lilly & Coe buys biotech Merida Biosciences for $2.875 billion, based on Eli's press release... ~ 31.08.2026, PRIM
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
